Patients with gliomas harbouring IDH1 or IDH2 mutations have been shown to have a decreased risk of thromboembolism, which may be related to a decreased expression of tissue factor, leading to a decrease in coagulation system activation [14,15]. This evidence concerns the gene IDH1 and central nervous system cancer.